SOURCE: Cardiovascular Sciences

March 05, 2008 08:30 ET

Cardiovascular Sciences, Inc. Pursues Agreement With Garden State Nutritionals

ORLANDO, FL--(Marketwire - March 5, 2008) - Cardiovascular Sciences, Inc. (PINKSHEETS: CVSC), a client company of the award-winning University of Florida Technology Incubator program and their recently announced partner, Medical Technologies Home Enterprises, Inc., are enthused to announce plans to pursue an agreement with Garden State Nutritionals of West Caldwell, NJ. The Company will negotiate for the manufacture, testing and packaging of a revised line of health promotion supplements with a tie-in to some of the Company's other interests.

John Martin, recently appointed to the Company's board of directors, has previously worked with Garden State to produce a very successful line of supplements that proved effective in the programs of Weight Loss Forever International, Inc. of which Mr. Martin was the founder and president. "It's exciting to develop a new offering of effective nutritionals and supplements with a company the quality and size of Garden State," exclaimed Mr. Martin following a pivotal meeting last week in Orlando.

Garden State Nutritionals is a division of Vitaquest International and the world's leading custom manufacturer of nutritional products. GSN has been under continuous family management for more than 30 years and boasts one of the world's largest and most compliant manufacturing and testing facilities for nutritional products. Long standing relationships with many of this industry's most well established and highly regarded names demonstrate evidence of the company's commitment to purity, quality and service. Drawing upon a palette of more than 1200 quality controlled ingredients, Garden State Nutritionals produces more than 2000 new products annually.

"We are pleased to have chosen Garden State for the production of our private label line of health promotion and protection products," states the Company's CEO, Dr. Larry Hooper. He goes on to explain that, "With their state-of-the-art technologies and equipment, Garden State is able to bring the same level of quality, regardless of the size of the batch. In addition, Garden State is fully GMP compliant and has been awarded the National Nutritional Foods Association coveted GMP 'A rating.'"

Arrangements have been made for representatives of Cardiovascular Sciences, Inc. to travel to the corporate and manufacturing facilities of Garden State Nutritionals in New Jersey next week. The goal of the intended meetings will be to finalize the formulations and line-ups of the Company's private label offerings and negotiate for the manufacture and packaging of the supplements.

About Cardiovascular Sciences

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals. The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development.

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

Contact Information

  • For more information contact:
    Cardiovascular Sciences Investor Relations